Zacks Research Issues Negative Forecast for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a note issued to investors on Wednesday, November 20th. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings per share of $2.62 for the quarter, down from their previous forecast of $2.67. The consensus estimate for AbbVie’s current full-year earnings is $10.95 per share. Zacks Research also issued estimates for AbbVie’s Q2 2025 earnings at $3.02 EPS, Q3 2025 earnings at $3.10 EPS, Q4 2025 earnings at $3.25 EPS, FY2025 earnings at $11.98 EPS, Q3 2026 earnings at $3.54 EPS and FY2026 earnings at $13.27 EPS.

Other equities analysts also recently issued research reports about the company. Bank of America lifted their price target on AbbVie from $185.00 to $195.00 and gave the company a “neutral” rating in a research note on Friday, October 18th. Guggenheim lifted their target price on AbbVie from $212.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. lowered their price target on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. BMO Capital Markets dropped their price objective on AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 12th. Finally, Wells Fargo & Company upped their target price on shares of AbbVie to $195.00 and gave the stock a “buy” rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $203.50.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $176.94 on Friday. AbbVie has a twelve month low of $137.65 and a twelve month high of $207.32. The stock’s 50 day moving average is $189.47 and its 200-day moving average is $181.04. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a market capitalization of $312.68 billion, a price-to-earnings ratio of 61.44, a PEG ratio of 2.03 and a beta of 0.63.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.92 by $0.08. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.95 EPS.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.71%. This is a boost from AbbVie’s previous quarterly dividend of $1.55. AbbVie’s dividend payout ratio (DPR) is presently 215.28%.

Institutional Investors Weigh In On AbbVie

Hedge funds have recently bought and sold shares of the stock. International Assets Investment Management LLC lifted its holdings in shares of AbbVie by 1,745.0% during the 3rd quarter. International Assets Investment Management LLC now owns 4,728,063 shares of the company’s stock worth $933,698,000 after acquiring an additional 4,471,806 shares during the last quarter. Swedbank AB bought a new position in shares of AbbVie during the first quarter valued at about $367,372,000. Price T Rowe Associates Inc. MD increased its holdings in shares of AbbVie by 13.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,744,190 shares of the company’s stock worth $1,956,518,000 after buying an additional 1,291,201 shares during the period. State Street Corp lifted its stake in shares of AbbVie by 1.6% in the 3rd quarter. State Street Corp now owns 79,067,935 shares of the company’s stock valued at $15,614,329,000 after acquiring an additional 1,267,685 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in AbbVie by 12.8% during the 1st quarter. Janus Henderson Group PLC now owns 10,898,246 shares of the company’s stock valued at $1,984,490,000 after acquiring an additional 1,240,434 shares during the period. 70.23% of the stock is currently owned by institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.